Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

Abstract

Background: The anti–PD-1 humanized monoclonal antibody pembrolizumab has recently been approved in the United States to treat metastatic non–small cell lung cancer (NSCLC) in patients (pts) who are PD-L1 positive and have progressed on platinum therapy and an EGFR/ALK inhibitor if EGFR/ALK positive. Here, we report on the prevalence of PD-L1 expression in pts screened for enrollment in 3 global clinical trials that investigated the efficacy and safety of pembrolizumab in pts with advanced NSCLC: KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), and KEYNOTE-024 (NCT02142738).